US Patent

US12178824 — Orodispersible formulations

Formulation · Assigned to Millicent Pharma Ltd · Expires 2041-06-24 · 15y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects an orodispersible formulation for contraception or hormone replacement therapy that has specific hardness, disintegration time, and friability.

USPTO Abstract

An orodispersible formulation for contraception or hormone replacement therapy containing an estrogen and a progestogen that has sufficient hardness, disintegration time and friability.

Drugs covered by this patent

Patent Metadata

Patent number: US12178824
Jurisdiction: US
Classification: Formulation
Expires: 2041-06-24
Drug substance claim: No
Drug product claim: Yes
Assignee: Millicent Pharma Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.